Home > Investor Relations > R&D > Basic Policy on Research

Basic Policy on Research

Chugai’s mission is to generate a steady stream of innovative products to address unmet medical need and benefit the medical community and human health around the world. Based on this principle, our key priority is to create new drugs with first-in-class*1 or best-in-class*2 potential.

In allocating research resources, we prioritize projects based on the following criteria:

Criteria for Allocation of Research Resources:
  • The compound’s potential for development as a novel medicine that can be clearly differentiated
  • Whether it has a scientific basis for addressing unmet medical need
  • Whether it is a project that will enable personalized healthcare (PHC)

At various decision points during research, we focus first and foremost on patient need, reflecting our belief that creating medicines truly needed by patients and healthcare providers will lead to Chugai’s medium-to-long-term growth.

*1  An original drug that is highly novel and useful, and will significantly change the therapeutic system
*2  A drug that offers clear advantages over other existing drugs in the same category, such as those with the same molecular target